Comparative Effectiveness of Anti-TNF Agents for Crohn’s Disease in a Tertiary Referral IBD Practice

[1] Van Deventer SJH(1997)Tumor necrosis factor and Crohn’s disease Gut 40 443-448

[2] Targan SR(1997)A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohns disease cA2 study group N Engl J Med 337 1029-1035

[3] Hanauer SB(2002)Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial Lancet 359 1541-1549

[4] van Deventer SJ(1999)Infliximab for the treatment of fistulas in patients with Crohn’s disease N Engl J Med 340 1398-1405

[5] Hanauer SB(2004)Infliximab maintenance therapy for fistulizing Crohn’s disease N Engl J Med 350 876-885

[6] Feagan BG(2006)Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial Gastroenterology 130 323-333

[7] Lichtenstein GR(2007)Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial Gastroenterology 132 52-65

[8] Present DH(2007)Adalimumab induction therapy for Crohn’s disease previously treated with infliximab: a randomized trial Ann Intern Med 146 829-838

[9] Rutgeerts P(2007)Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti tumor necrosis factor alpha agents Inflamm Bowel Dis 13 1323-1332

[10] Targan S(2007)Certolizumab pegol for the treatment of Crohn’s disease N Engl J Med 357 228-238

[1] Van Deventer SJH(1997)Tumor necrosis factor and Crohn’s disease Gut 40 443-448

[2] Targan SR(1997)A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohns disease cA2 study group N Engl J Med 337 1029-1035

[3] Hanauer SB(2002)Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial Lancet 359 1541-1549

[4] van Deventer SJ(1999)Infliximab for the treatment of fistulas in patients with Crohn’s disease N Engl J Med 340 1398-1405

[5] Hanauer SB(2004)Infliximab maintenance therapy for fistulizing Crohn’s disease N Engl J Med 350 876-885

[6] Feagan BG(2006)Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial Gastroenterology 130 323-333

[7] Lichtenstein GR(2007)Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial Gastroenterology 132 52-65

[8] Present DH(2007)Adalimumab induction therapy for Crohn’s disease previously treated with infliximab: a randomized trial Ann Intern Med 146 829-838

[9] Rutgeerts P(2007)Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti tumor necrosis factor alpha agents Inflamm Bowel Dis 13 1323-1332

[10] Targan S(2007)Certolizumab pegol for the treatment of Crohn’s disease N Engl J Med 357 228-238